Genezen’s new viral vector process development lab

Scroll Down

Our new state-of-the-art, cGMP-compliant multi-vector process development facility is now open!

Our deep expertise in development and manufacture of viral vectors coupled with this new facility and equipment will accelerate our partners’ abilities to advance life-saving therapies into the clinic.

The lab will deliver a full suite of process development capabilities to support cGMP and commercial readiness, upstream and downstream process improvements, research grade and preclinical vector production, and analytical assay development and validation from the site. Learn more about the facility’s capabilities here.

You may also be interested in...

Genezen completes cGMP-lentiviral and retroviral vector…

Genezen, a cell and gene therapy Contract Development and Manufacturing Organization...

Read more

Genezen announces launch of Scientific Advisory…

Leading experts in cell and gene therapy will provide guidance to...

Read more

Overcoming development and manufacturing challenges with…

As efficient and effective tools for gene transduction and delivering genes...

Read more

Retroviruses in CAR-T therapies: From gamma…

Introduction In recent years, chimeric antigen receptor T (CAR-T) cells have...

Read more